BioCentury | Jan 27, 2014
Finance

Going big

...a final close next half. Institutional investors that have committed to the new fund include Natixis Private Equity...
BioCentury | Jul 12, 2010
Finance

Kurma expands Footprint

...maximum of €6 million over several tranches or rounds. LPs in Kurma Biofund I include Natixis Private Equity...
BioCentury | Jan 11, 2010
Financial News

EyeGate completes venture financing

...Date completed: 1/8/10 Type: Venture financing Raised: $22.6 million Investors: Ventech; Innoven Partners; Medicis Capital; Natixis Private Equity...
BioCentury | Jan 9, 2010
Financial News

EyeGate raises $22.6 million

...Inc. (Waltham, Mass.) raised $22.6 million in a series D round led by new investor Natixis Private Equity...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...biotechs, including metabolic disorder company DeveloGen , immunotherapy company IDM and ophthalmology company Neurotech . Natixis Private Equity...
Items per page:
1 - 5 of 5
BioCentury | Jan 27, 2014
Finance

Going big

...a final close next half. Institutional investors that have committed to the new fund include Natixis Private Equity...
BioCentury | Jul 12, 2010
Finance

Kurma expands Footprint

...maximum of €6 million over several tranches or rounds. LPs in Kurma Biofund I include Natixis Private Equity...
BioCentury | Jan 11, 2010
Financial News

EyeGate completes venture financing

...Date completed: 1/8/10 Type: Venture financing Raised: $22.6 million Investors: Ventech; Innoven Partners; Medicis Capital; Natixis Private Equity...
BioCentury | Jan 9, 2010
Financial News

EyeGate raises $22.6 million

...Inc. (Waltham, Mass.) raised $22.6 million in a series D round led by new investor Natixis Private Equity...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...biotechs, including metabolic disorder company DeveloGen , immunotherapy company IDM and ophthalmology company Neurotech . Natixis Private Equity...
Items per page:
1 - 5 of 5